[SCHEDULE 13D/A] Vor Biopharma Inc. SEC Filing

Rhea-AI Filing Summary

Amendment No. 1 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman together beneficially own 36,884,567 shares of Vor BioPharma Inc., representing 29.1% of the outstanding Common Stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25–28, 2025, totaling 2,089,534 shares. Reported weighted-average sale prices were $2.1163 on August 25, $2.0808 on August 26, $2.0053 on August 27 and $2.0115 on August 28. The filing states these sales reduced the Reporting Persons' holdings by more than one percent of the outstanding shares and otherwise incorporates prior Schedule 13D disclosures.

Positive

• Transparency: The Reporting Persons promptly amended Schedule 13D to disclose open-market sales exceeding the one-percent threshold
• Remaining stake: Reporting Persons continue to beneficially own a substantial 29.1% stake, preserving significant influence

Negative

• Disposition of shares: Sale of 2,089,534 shares over four days reduced their economic exposure
• Market timing: Weighted-average sale prices were near or below $2.12, indicating liquidation at modest prices

Insights

Financial Analyst

TL;DR: A >2.08M-share block was sold over four days, modestly reducing a near-30% stake; routine disclosure of open-market liquidity sales.

The reporting persons remain a large shareholder with 36,884,567 shares (29.1%) after the transactions. The four-day sale pattern and sub-$2.12 weighted average prices suggest the seller used open-market trades to monetize part of the position rather than a single block sale or a negotiated transaction. No additional purchases or other transactions in the prior 60 days are reported. This disclosure is material because it documents a multi-day reduction exceeding one percent of the outstanding class, but the filing does not state any change in control intentions or new arrangements.

Corporate Governance Expert

TL;DR: Significant shareholder executed scheduled open-market sales; filing complies with Schedule 13D amendment requirements.

The amendment confirms continued shared voting and dispositive power over 36,884,567 shares. The sale of 2,089,534 shares was disclosed promptly via this Schedule 13D/A, addressing the regulatory threshold for amendments. The document indicates no new contracts, arrangements, or legal proceedings related to the securities. From a governance perspective, the Reporting Persons remain a prominent stakeholder but have partially reduced economic exposure through market sales.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $.0001 per share

(Title of Class of Securities)

929033108

(CUSIP Number)

Frank Huang, Manager
101 Mission Street, Suite 1000,
San Francisco, CA, 94105
(415) 541-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/27/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reprogrammed Interchange LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 36,884,567.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 36,884,567.00

11

Aggregate amount beneficially owned by each reporting person

36,884,567.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

29.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reid Hoffman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 36,884,567.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 36,884,567.00

11

Aggregate amount beneficially owned by each reporting person

36,884,567.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

29.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $.0001 per share
(b)	Name of Issuer: VOR BIOPHARMA INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Cambridgepark Drive, Suite 101, Cambridge, MASSACHUSETTS , 02140.
Item 1 Comment: This Amendment No. 1 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on Janauary 7, 2025 (the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 1 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Item 4 of Schedule 13D is hereby amended and supplemented as follows: From August 25, 2025 through August 28, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outsanding shares of Common Stock of the Issuer. 1. 387,346 shares on August 25, 2025, at a weighted average per share sale price of $2.1163. 2. 284,190 shares on August 26, 2025, at a weighted average per share sale price of $2.0808. 3. 611,647 shares on August 27, 2025, at a weighted average per share sale price of $2.0053. 4. 806,351 shares on August 28, 2025, at a weighted average per share sale price of $2.0115.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 1 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	Except as set forth in Item 4 above, none of the Reporting Persons has effected any transactions in the Common Stock of the Issuer during the last 60 days.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Reprogrammed Interchange LLC

Signature:	/s/ Frank Huang
Name/Title:	Frank Huang, Manager
Date:	08/29/2025

Reid Hoffman

Signature:	/s/ Reid Hoffman
Name/Title:	Reid Hoffman
Date:	08/29/2025

FAQ

How many Vor Biopharma (VOR) shares do the Reporting Persons now beneficially own?

They beneficially own 36,884,567 shares, representing 29.1% of the outstanding common stock.

How many shares were sold and on what dates in the Schedule 13D/A?

Reprogrammed Interchange LLC sold a total of 2,089,534 shares across four dates: 387,346 on Aug 25, 284,190 on Aug 26, 611,647 on Aug 27 and 806,351 on Aug 28, 2025.

What weighted-average prices were reported for the sales?

Weighted-average sale prices reported were $2.1163 (Aug 25), $2.0808 (Aug 26), $2.0053 (Aug 27) and $2.0115 (Aug 28), 2025.

Did the filing report any new agreements, arrangements, or legal proceedings?

No. Item 6 states not applicable and no legal proceedings are disclosed in this amendment.

Were there any other transactions in the last 60 days reported?

Except for the transactions described in Item 4, the Reporting Persons state they have not effected any transactions in the issuer's common stock during the last 60 days.